Jun Wei1, Jun Sun2, Xuefen Shuai3, Junqing Ren4, Xuedong Chen5. 1. Jun Wei, Department of Respiratory and Critical Medicine, Xuancheng People's Hospital, Xuancheng 242000, Anhui, China. 2. Jun Sun, Department of Respiratory and Critical Medicine, Xuancheng People's Hospital, Xuancheng 242000, Anhui, China. 3. Xuefen Shuai, Department of Respiratory and Critical Medicine, Xuancheng People's Hospital, Xuancheng 242000, Anhui, China. 4. Junqing Ren, Department of Respiratory and Critical Medicine, Xuancheng People's Hospital, Xuancheng 242000, Anhui, China. 5. Xuedong Chen, Department of Respiratory and Critical Medicine, Xuancheng People's Hospital, Xuancheng 242000, Anhui, China.
Pulmonary tuberculosis (PTB) is a contagious bacterial infection of the lungs caused by the bacterium Mycobacterium tuberculosis (M. tb), which spreads easily from an infected person to others by the airborne route.1,2 Constantly improved treatment options mean that most PTB patients can be cured with timely diagnosis and treatment.3 With laboratory (lab) tests being the key to PTB diagnosis4, it is essential to improve the diagnostic performance of PTB screening tests to achieve early diagnosis and effective prevention and control of the disease.5 Currently, laboratory tests such as sputum smear, sputum culture, sputum stain for M. tb (acid-fast stain, AFS), lipoarabinomannan (LAM) antigen test (LAM-TB), and serum adenosine deaminase (ADA) test are commonly used for the diagnosis of PTB but have low positive predictive values. Against this background, molecular biological testing has been increasingly discussed in the field of PTB prevention and control to optimize PTB pathogen detection and identification.6This study was done to observe the sensitivity of BALF melting curve method in the diagnosis of pulmonary tuberculosis and explore the clinical application value of BALF melting curve method in the diagnosis of pulmonary tuberculosis, 214 patients with bronchoscopic alveolar lavage fluid (BALF) were detected by polymerase chain reaction (PCR) using fluorescence probe melting curve method and automatic medical PCR analysis system7,8 in this study.
METHODS
A total of 214 PTB patients who were treated at Xuancheng People’s Hospital hospital between during January 2018 to January 2021 were included in this study. There were 97 males and 117 females, with the mean age of (36.54 ±13.27) years (range: 18-74). In terms of severity of lung involvement, one pulmonary lesion was found in 162 patients, while two or more were detected in the rest 62 patients. Clinical manifestations were cough and productive cough (n =208), fever (n =154), hemoptysis (n =61), and fatigue (n =184). Imaging features included fibrous streaks (n =127), cavities (n =113), multiple diffuse nodules (n =27), ground-glass opacities (n =22), and multi-segment effusion/consolidation (n =31).
Ethical Approval:
The study was approved by the Institutional Ethics Committee of Xuancheng People’s Hospital on June 16, 2019(No.:2017020), and written informed consent was obtained from all participants.
Inclusion criteria:
A patient was rendered eligible for this study if he/she:Met the diagnostic criteria for PTB;9Aged between 18 and 75;Agreed to receive bronchoscopic alveolar lavage fluid polymerase chain reaction (melting curve method) examination, BALF smear, BALF culture, LAM-TB, AFS, and ADA tests;Had knowledge of this study and agreed to sign an informed consent.
Exclusion Criteria:
Complications such as bronchogenic cancer, bronchial asthma, and chronic obstructive pulmonary disease;Incomplete test results;Confirmed mental disorders or cognitive impairment.LAM-TB, AFS, and ADA were performed during the hospital stay, while screening for contraindications to flexible bronchoscopy was completed before routine bronchoscopy. Bronchoalveolar lavage (BAL) was carried out by locating the affected lobes and segments via bronchoscopy and chest imaging. Disposable cytology brushes, lavage equipment, and 100-150 mL of stroke-physiological saline solution (SPSS) at 37°C were used for BAL, where negative pressure (50-80 mmHg) was applied to collect 50-75 ml of BALF for smear preparation. Then smear of BALF, culture of Mycobacterium tuberculosis in BALF and polymerase chain reaction performed melting curve method were operated in strict accordance with the kit instructions. The melting curve analysis system and its kit were purchased from Xiamen Zhishan Biotechnology Co., Ltd.
Statistical Analysis:
Data processing was conducted using SPSS23.0. Measurement data were expressed as “mean ± standard deviation (m±sd)”, and enumeration data was represented by rates or percentages. The comparison was examined by the χ2 test, with results at a level lower than 0.05 as statistically significant.
RESULTS
By comparing the positive results produced by different PTB screening tests, it was found that BALF melting curve method had a PPV (84.11%) higher than other diagnostic approaches, including LAM-TB (69.16%), AFS (51.87%), ADA (49.07%), BALF culture (62.15%), and BALF smear (41.12%) (p<0.05, respectively). Table-I.
Table I
PPV comparison among different PTB screening tests.
Lab Test
Total Cases (n)
Negative Cases (n)
Positive Cases (n)
PPV (%)
LAM-TB
214
66
148
69.16[*]
AFS
214
103
111
51.87[*]
ADA
214
54
160
74.76[*]
BALF culture
214
81
133
62.15[*]
BALF smear
214
126
88
41.12[*]
BALF melting curve method
214
34
180
84.11
p<0.05 compared with BALF melting curve method.
PPV comparison among different PTB screening tests.p<0.05 compared with BALF melting curve method.PPVs were 92.06%, 93.93%, 92.99%, 95.79%, and 91.12% when BALF melting curve method was performed in combination with LAM-TB, AFS, ADA, BALF culture, and BALF smear, respectively, which were significantly higher than the PPVs of BALF melting curve method alone and the combined use of two non-BALF melting curve method tests (p<0.05, respectively). Table-II.
Table II
Comparison of diagnostic results by combined use of two PTB screening tests.
Lab Test
Add-on Test
Total Cases (n)
Negative Cases (n)
Positive Cases (n)
PPV (%)
BALF melting curve method
LAM-TB
214
17
197
92.06[*Δ]
AFS
214
13
201
93.93[*Δ]
ADA
214
24
199
92.99[*Δ]
BALF culture
214
9
205
95.79[*Δ]
BALF smear
214
19
195
91.12[*Δ]
LAM-TB
AFS
214
60
154
71.96
ADA
214
37
177
82.71
BALF culture
214
42
172
80.37
BALF smear
214
51
163
76.17
AFS
ADA
214
41
173
80.81
BALF culture
214
60
154
71.96
BALF smear
214
73
141
65.89
ADA
BALF culture
214
38
176
82.24
BALF smear
214
34
180
84.11
BALF culture
BALF smear
214
58
156
72.90
p<0.05 compared with BALF melting curve method;
p<0.05 compared with any two of the non-BALF melting curve method tests.
Comparison of diagnostic results by combined use of two PTB screening tests.p<0.05 compared with BALF melting curve method;p<0.05 compared with any two of the non-BALF melting curve method tests.
DISCUSSION
PTB is the world’s leading infectious disease that threatens public health worldwide. China has approximately 1.3 million new PTB cases every year, which accounts for 14.3% of the world’s annual incidence, ranking second among the high PTB-burden countries. Although China has made impressive progresses in PTB prevention and control, it is still one of the countries heavily burdened with the disease and faced with the enormity of the nationwide TB epidemic.10 At present, clinical diagnosis of PTB mainly depends on imaging, lab tests and observation of clinical manifestations and treatment outcomes11, among which lab tests are the mainstay of final diagnosis and sputum smear and culture of M. tb as the “gold standard”.12 Although sputum smear is inexpensive and easy-to-administer as a PTB screening test, it has a relatively low PPV and is less sensitive to sputum culture, which is comparatively time-consuming and highly responsive to anti-TB treatment. Therefore, bacteriological examination of sputum is considered to have a low PPV in PTB diagnosis.13LAM-TB relies on western blotting and monoclonal antibody detection to identify M. tb and 12 other pathogenic Mycobacterium spp. in patients with suspected PTB, which has a relatively high PPV by purification of TB-specific peptide antigens based on immunogenicity and serum M. tb-specific antibody profiles.14 In this study, LAM-TB had a PPV of 69.16%, basically consistent with the study by Wang YM et al.15, where the LAM-TB test results showed that 72.1% of the culture-positive patients and 45.6% of the culture-negative patients had PTB. ADA is an important hydrolase involved in purine nucleotide metabolism. In blood, ADA primarily exists in erythrocytes, granulocytes, and lymphocytes. The ADA level is associated with lymphocyte activation and differentiation. In PTB cases, the substantial increase in the ADA level is suggested to result from enhanced T cell-mediated immunity.16 Zhang C et al.17 reported that the serum ADA level in PTB patients was significantly higher than in healthy individuals [(37.35 ±4.68) U/L vs (12.11 ±3.23) U/L]. This study showed that the ADA test had a PPV of 74.72% in the diagnosis of PTB.BALF from the affected bronchi is characterized by a relatively high bacterial concentration and a low risk of contamination.18 If timely delivered to laboratories, BALF smear and culture can produce PPVs higher than sputum smear and culture. BALF smear results can be obtained within the day of sampling, and yet the PPV is lower than BALF culture, which, however, needs more time to produce a higher PPV. To some extent, these screening tests may hinder the early diagnosis and treatment of PTB.19 PCR is a technique that amplifies DNA and RNA in vitro through DNA replication.20 PCR assays for M. tb detection have the following advantages: 1) bacteria at a concentration lower than the detectable levels of regular screening tests can be identified after DNA or RNA amplification, which is beneficial to the early diagnosis of PTB21; 2) PCR assays are more sensitive to PTB without cavitation compared with traditional approaches; 3) in addition to viable bacteria, dead bacteria without DNA degradation can also be amplified to identify lesions in the lungs and prevent missed or erroneous diagnosis;22 4) PCR reagents work in parallel with anti-TB drugs to examine whether M. tb DNA has been completely degraded through quantitative determination. Fluorescence PCR probe melting curve method (melt Pro ® TB tuberculosis integrated detection system) has many detection sites, high sensitivity, strong specificity, and fast speed, the results of which can be obtained in 2-3 hours. With patients being able to receive their test results on the day of sampling, it can assist the early diagnosis and timely treatment of PTB. melting curve method assay of BALF is demonstrated to improve the PPV from 60-70% to a higher level in PTB diagnosis.15 In this study, BALF melting curve method has a PPV of 84.11%, outperforming LAM-TB, AFS, ADA, BALF culture, and BALF smear used for the diagnosis of PTB. Moreover, BALF melting curve method has a higher PPV with LAM-TB, AFS, ADA, BALF culture, or BALF smear as an add-on test (PPV =92.06%, 93.93%, 92.99%, 95.79%, and 91.12%, respectively), demonstrating a higher degree of sensitivity for PTB diagnosis compared with BALF melting curve method alone and the combined use of two non-BALF melting curve method tests.
Limitations of the study:
It includes small sample are included in the study, short follow-up time, and failure to divide and study the post-operative pathological types, therapeutic effects and prognosis of patients in a more detailed manner due to small sample size. In view of this, proactive countermeasures will be taken in the future to carry out more comprehensive studies on such patients, so that more scientific data can be made available to our clinicians.
CONCLUSION
This study demonstrated that BALF melting curve method is an effective PTB screening test of a diagnostic value higher than LAM-TB, AFS, ADA, BALF culture, and BALF smear. In addition, it can be used for the detection of rifampicin-resistant TB. Therefore, it is an ideal laboratory test for PTB diagnosis.
Authors’ Contributions:
JW & JS: Designed this study,prepared this manuscript, are responsible and accountable for the accuracy or integrity of the work.XS & XC: Collected and analyzed clinical data.JR: Significantly revised this manuscript.
Authors: Sang Hoon Lee; Ji Yeon Sung; Dongeun Yong; Jongsik Chun; Song Yee Kim; Joo Han Song; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Se Kyu Kim; Joon Chang; Moo Suk Park Journal: Lung Cancer Date: 2016-10-31 Impact factor: 5.705